U.S. Colorectal Cancer Screening Market to Grow Rapidly with Advanced Non-Invasive Tests

U.S. Colorectal Cancer Screening Market to Grow Rapidly with Advanced Non-Invasive Tests

The U.S. Colorectal Cancer Screening Market encompasses a range of diagnostic products including fecal immunochemical tests (FIT), colonoscopy devices, stool DNA assays and emerging blood-based biomarkers. These solutions offer early detection advantages such as higher sensitivity, reduced procedural risk and improved patient compliance compared to traditional methods. Rising incidence of colorectal cancer among aging populations and the need for routine preventive care have amplified demand for both invasive and non-invasive screening modalities.

U.S. Colorectal Cancer Screening Market Market research underscores an increased preference for at-home testing kits that streamline sample collection and telehealth integrations that facilitate remote monitoring. As healthcare providers and insurers prioritize cost-effective, patient-centric diagnostics, manufacturers are investing in automation, CE-marked consumables and digital reporting platforms to enhance throughput and data interoperability.

The U.S. colorectal cancer screening market size was valued at US$ 6.41 Bn in 2025 and is expected to reach US$ 10.77 Bn by 2032, grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2032.

Key Takeaways

Key players operating in the U.S. Colorectal Cancer Screening Market are Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Quidel Corporation and Novigenix SA. These market players dominate industry share through extensive distribution networks, robust R&D pipelines and strategic collaborations with clinical laboratories and hospital systems. Their combined efforts shape market dynamics and influence market growth strategies across diagnostic segments.

Growing demand for early detection tools is driven by rising colorectal cancer incidence, heightened public awareness campaigns and expanding preventive screening guidelines from bodies like the U.S. Preventive Services Task Force. Market insights reveal increasing adoption of non-invasive stool-based tests, spurred by patient preference for at-home sampling and lower out-of-pocket costs. This demand surge is also bolstered by telehealth expansion and digital health platforms that provide appointment scheduling, results reminders and follow-up care coordination, fostering business growth for service providers and device manufacturers alike.

Technological advancement remains a core market driver, with innovations such as next-generation sequencing (NGS) for multi-gene panels, AI-powered image analysis in colonoscopy and novel blood-based biomarker assays. These developments enhance diagnostic accuracy and workflow efficiency while addressing market challenges like variable sensitivity and patient compliance. Integration of cloud-based reporting tools and wearable biosensors further refines real-time patient monitoring, positioning the market for sustained market growth and diversification.

Market Trends
One key trend in the U.S. Colorectal Cancer Screening Market is the integration of artificial intelligence (AI) and machine learning into colonoscopy procedures. AI-driven polyp detection systems improve adenoma detection rates, reduce miss rates and standardize reporting, leading to better patient outcomes and operational efficiencies.

The adoption of AI tools is supported by favorable reimbursement policies and partnerships between technology vendors and clinical research organizations, reflecting evolving industry trends toward precision diagnostics.
Another significant trend is the shift toward at-home stool DNA and immunochemical testing. Equipped with mail-in kits and smartphone apps, these solutions cater to patients reluctant to undergo invasive procedures. Manufacturers are enhancing test sensitivity and specificity through proprietary reagent formulations and streamlined workflows, enabling broader adoption across primary care settings and community health programs. This trend addresses market restraints such as limited endoscopy capacity and geographic disparities in healthcare access.

Market Opportunities
The rise of telehealth and digital therapeutics presents a major opportunity for market companies to offer integrated screening services. By combining remote consultations, e-prescriptions for at-home kits and real-time result tracking, providers can enhance patient engagement and adherence. Collaborations between telemedicine platforms and diagnostic manufacturers can create bundled service models that reduce barriers to screening and stimulate market revenue growth.

A second opportunity lies in biomarker-driven personalized screening protocols. Advances in genomics and proteomics enable risk stratification based on family history, lifestyle factors and molecular signatures. Companies that develop multiplex assays capable of detecting multiple biomarkers simultaneously can tap into this niche. Strategic alliances between biotech firms and academic research centers will foster co-development of next-generation diagnostics, driving market opportunities in precision medicine and expanding the overall industry size.

Section 1: Impact of COVID-19 on Market Growth, Pre-COVID and Post-COVID Scenario, and Future Strategies
The onset of the COVID-19 pandemic created a significant disruption in the U.S. colorectal cancer screening market. Pre-COVID, routine screenings such as colonoscopy and non-invasive fecal tests were scheduled through well-established hospital networks and outpatient centers. Screening rates were rising steadily, driven by awareness campaigns and reimbursement incentives. Early detection programs benefited from streamlined workflows and collaborations among diagnostic labs, gastroenterologists, and payers, fueling steady market growth and positive market dynamics.

During the pandemic’s peak, elective procedures were deferred, leading to a sharp decline in screening volumes. Many patients postponed routine visits due to infection fears and lockdown measures, creating a backlog of delayed colonoscopies and non-invasive tests. Supply chain restraints hampered availability of endoscopy equipment and reagents, while budget cuts and resource reallocation to COVID wards became key market restraints. Healthcare providers faced market challenges in ramping back up, with limited staff and heightened sanitation protocols extending turnaround times.

As the sector moved into recovery, post-COVID strategies have focused on telehealth triage, value-based reimbursement and decentralized testing. Providers are leveraging at-home testing kits, digital reminders and risk-stratification algorithms to improve patient compliance. Market insights reveal growing interest in blood-based biomarkers and mobile screening units to reach underserved communities. Future market growth strategies involve strengthening public–private partnerships, enhancing real-world evidence generation and investing in AI-driven analytics to optimize screening intervals. Emphasizing patient education, digital engagement platforms and flexible scheduling will help address ongoing market challenges while seizing emerging market opportunities in a hybrid care model.

Section 2: Geographical Regions Where Value Is Concentrated
Within the United States, value concentration in colorectal cancer screening tends to correlate with population density, healthcare infrastructure and private-public funding initiatives. The East Coast—anchored by major academic centers in New York, Massachusetts and Pennsylvania—accounts for a sizeable industry share, driven by sophisticated endoscopy suites and advanced diagnostic labs. These states benefit from robust reimbursement pathways and an established network of Market Research efforts guiding best practices.

On the West Coast, California and Washington lead in total screening revenue, supported by large managed-care organizations and proactive state policies that emphasize preventive care. The presence of biotech hubs accelerates adoption of cutting-edge non-invasive assays and digital pathology, reinforcing this region’s market scope. In the Midwest, states such as Illinois and Ohio register moderate volumes; however, ongoing outreach programs and Federally Qualified Health Centers are expanding access, gradually increasing industry size.

The South—particularly Texas and Florida—has emerged as a significant contributor to overall market share. Large, diverse populations and rising incidence rates have prompted health systems to deploy mobile screening vans and community health fairs. Despite historical under-penetration, aggressive public health campaigns have begun to shift market segments in favor of earlier detection, enhancing market revenue concentration in this geography. Across all regions, a combination of regulatory support, payer incentives and targeted awareness campaigns underpins concentrated value pools, providing a foundation for sustained business growth.

Section 3: Fastest-Growing Region
The Western United States currently stands out as the fastest-growing region for colorectal cancer screening. High per-capita healthcare spending, ready access to advanced diagnostics and a tech-savvy patient base foster rapid uptake of innovative screening modalities, from virtual colonoscopy to biomarker-based blood tests. Silicon Valley–area companies and academic spin-offs collaborate closely with regional health systems, driving market innovations and accelerating clinical validation. These market drivers are complemented by progressive payer policies that reimburse new diagnostic platforms, creating attractive market opportunities for device manufacturers and service providers.

In addition, Western states have been early adopters of telehealth regulations, allowing physicians to triage patients virtually and prescribe at-home testing kits, which has further reduced procedural bottlenecks. This regulatory agility, combined with strong venture capital interest, enhances the market forecast for the region. Market analysis highlights that population subgroups with limited mobility—rural residents in California’s Central Valley or agricultural communities in Oregon—are being reached via mobile clinics and community health partnerships, further boosting segment growth.

Emerging alliances between tech companies and health systems are developing AI-driven risk-assessment tools, promising to optimize screening intervals and reduce unnecessary procedures. With continued investment in infrastructure, data interoperability and patient engagement platforms, the Western U.S. is poised to maintain a leading trajectory in colorectal cancer screening, capturing a disproportionate share of business growth and setting the pace for national adoption.

Get More Insight On : U.S. Colorectal Cancer Screening Market

Get this Report in Japanese Language: 米国大腸がん検査市場

Get this Report in Korean Language: 미국대장암검진시장

Read More Related Articles- Understanding Colorectal Cancer Screening in the United States

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)